Navigation Links
Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinson's Disease Hits Major Milestone
Date:9/30/2009

New molecules may be an alternative therapy for Parkinson's

NEW YORK, Sept. 30 /PRNewswire-USNewswire/ -- Michael J. Fox Foundation-funded researchers at Vanderbilt University Medical Center have reached a milestone in the development of potential new drugs for Parkinson's disease that may avoid the limitations of current therapy.

The team, which received an MJFF award of up to $4.4 million under the Foundation's 2007 LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative, has identified two drug-like molecules that, when given systematically in a pre-clinical model of Parkinson's disease, reduce PD symptoms by acting on a specific glutamate receptor in the brain called the metabotropic glutamate receptor, or mGluR4.

Jeffrey Conn, PhD, director of the Vanderbilt Drug Discovery Program and leader of the research team, will detail the discovery in a presentation called "Discovery of mGluR4 Potentiators for Symptomatic and Disease-modifying Treatment of PD" at the third annual Parkinson's Disease Therapeutics Conference, hosted today in New York City by The Michael J. Fox Foundation and The New York Academy of Sciences.

"If we can develop a molecule that has the right properties and does not have toxicity, we really believe this has an opportunity to have a major impact for Parkinson's patients," said Conn. "Nothing could be more exciting than that... Nothing could be more satisfying."

"Obviously there are no guarantees," Dr. Conn cautioned. But if progress continues, clinical trials in patients with Parkinson's disease could begin sometime in 2013, he said.

In previous studies, Conn and others have found that they could relieve symptoms of Parkinson's disease in pre-clinical models by activating the mGluR4 receptor.

In their latest finding, the Vanderbilt researchers have found two compounds that act on mGluR4 and, when given systemically in a pre-clinical model of Parkinson's disease, get to the brain and relieve motor symptoms, including rigidity and akinesia or a "freezing" of certain motor muscles. Further pre-clinical testing will be required before tests in humans can begin. But, said Conn, the identification of these molecules is "a big step forward."

Dr. Conn's colleagues in this effort include Colleen Niswender, PhD, Corey Hopkins, PhD, Carrie Jones, PhD, Craig Lindsley, PhD, and David Weaver, PhD, each of whom directs critical components of this large multidisciplinary effort.

More information, including a detailed Q&A with Jeff Conn, is available on The Michael J. Fox Foundation's Web site at www.michaeljfox.org/research.

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded $149 million in research to date.

SOURCE Michael J. Fox Foundation


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 2010
2. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
3. Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinsons Therapeutic Targets
4. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
5. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
6. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
7. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
8. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
9. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):